Antimicrobial resistance in bacteria is problematic in clinical settings and is a growing threat to public health. Multidrug-resistant and pandrug-resistant non-fermenters such as Acinetobacter spp. and Pseudomonas aeruginosa have recently emerged as a great concern worldwide. Particularly, the prevalence of carbapenem resistance in Acinetobacter spp. and P. aeruginosa is problematic, and emergence of polymyxin resistance is ominous. In this review, we discuss carbapenem and polymyxin resistance in Acinetobacter spp. and P. aeruginosa isolates and their major clones.
(AIDS) are particularly at risk to P. aeruginosa infections.
NNIS data from 1986~1998 has identified P. aeruginosa as the fifth most frequently isolated nosocomial pathogen (7) . P. aeruginosa is the second most common cause of healthcare-associated pneumonia including ventilatorassociated pneumonia (8) . As P. aeruginosa as well as Acinetobacter spp. cannot ferment glucose and they are closely related phylogenetically, they are frequently classified together as 'non-fermenters'.
Antimicrobial resistance in Acinetobacter spp. and P. aeruginosa
Antimicrobial resistance among Acinetobacter spp.
isolates has increased substantially in recent years (9) . The emergence of multidrug-resistant (MDR) Acinetobacter spp.
isolates has become a serious clinical concern worldwide (3) . A. baumannii is generally intrinsically resistant to a number of commonly used antimicrobial agents such as aminopenicillins, cephalosporins, and chloroamphenicol.
In addition, it has shown a remarkable capacity to acquire resistance to broad-spectrum-β-lactams, aminoglycosides, fluoroquinolones, and tetracyclines (10) . Such extensive antimicrobial resistance in A. baumannii may be due in part to the organism's relatively impermeable outer membrane and its environmental exposure to a large reservoir of resistance genes (11) .
Outbreaks by MDR A. baumannii isolates have occurred worldwide, and even isolates resistant to most commercially available agents (pandrug resistance, or PDR) are also emerging (3, 12) . Of particular concern is resistance to carbapenems such as imipenem and meropenem. Carbapenems are usually recommended as a potent antimicrobial agent against A. baumannii infections (13 showing activity against most β-lactams have primarily been described in Klebsiella pneumoniae, and rarely in P.
aeruginosa. For GES, GES-2, and GES-5 have been reported in P. aeruginosa isolates.
Among the five families of efflux pump systems so far described in bacteria, the Resistance Nodulation Division (RND) family is the most significant in the antimicrobial resistance of P. aeruginosa. Of the RND-type efflux pump systems, MexAB-OprM, MexCD-OprJ, and MexXY-OprM contribute to the resistance to carbapenems (7). However, the efflux pump is a minor contributor to carbapenem resistance in P. aeruginosa (28) . The most common mechanism of resistance to the carbapenems in P. aeruginosa is loss or alteration of the outer membrane porin protein OprD (35 (20, 37, 38) .
In several Gram-negative species, colistin resistance is (61) . In particular, the association between ST235 and IMP-6 in South Korea (67, 68) is noteworthy.
Because IMP-6 induces high-level meropenem resistance, the combination of the worldwide clone and potent MBL is troubling.
In addition to the two international clones, some CF clones of P. aeruginosa such as CC146, CC148, and CC406
have also been reported worldwide since the late 1990s (69).
These CF clones often have hypermutable phenotype (i.e., a 'pan-resistant' phenotype), but rarely possess carbapenemases (65) . CC277 also has a worldwide distribution and SPM-1-positive isolates have been were found in Brazil.
CC175 has been identified in many European countries, and VIM-2-producing CC175 isolates have been described in Germany.
The emergence and spread of carbapenem-or polymyxinresistant Acinetobacter spp. and P. aeruginosa isolates is a great concern worldwide, especially in South Korea. The understanding of their epidemiology and resistance mechanisms will help to combat the threat posed by antimicrobial resistance.
